These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18092832)

  • 41. Computer graphic modeling in drug design--conformational analysis of antifolate binding to avian dihydrofolate reductase: crystal and molecular structures of 2,4-diamino-5-cyclohexyl-6-methylpyrimidine and 5-cyclohexyl-6-methyluracil.
    Cody V; Ciszak E
    Anticancer Drug Des; 1991 May; 6(2):83-93. PubMed ID: 2039584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints.
    Kumar A; Siddiqi MI
    J Mol Graph Model; 2008 Nov; 27(4):476-88. PubMed ID: 18829358
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro.
    Suling WJ; Maddry JA
    J Antimicrob Chemother; 2001 Apr; 47(4):451-4. PubMed ID: 11266419
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Crystal structures of Escherichia coli dihydrofolate reductase complexed with 5-formyltetrahydrofolate (folinic acid) in two space groups: evidence for enolization of pteridine O4.
    Lee H; Reyes VM; Kraut J
    Biochemistry; 1996 Jun; 35(22):7012-20. PubMed ID: 8679526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Dual-Targeting Activity of the Metabolite Substrate of Para-amino Salicyclic Acid in the Mycobacterial Folate Pathway: Atomistic and Structural Perspectives.
    Agoni C; Ramharack P; Salifu EY; Soliman MES
    Protein J; 2020 Apr; 39(2):106-117. PubMed ID: 32086691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.
    Schormann N; Velu SE; Murugesan S; Senkovich O; Walker K; Chenna BC; Shinkre B; Desai A; Chattopadhyay D
    Bioorg Med Chem; 2010 Jun; 18(11):4056-66. PubMed ID: 20452776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry.
    Cody V; Luft JR; Pangborn W; Gangjee A; Queener SF
    Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):646-55. PubMed ID: 15039552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
    Rosowsky A; Fu H; Chan DC; Queener SF
    J Med Chem; 2004 May; 47(10):2475-85. PubMed ID: 15115391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
    Forsch RA; Queener SF; Rosowsky A
    Bioorg Med Chem Lett; 2004 Apr; 14(7):1811-5. PubMed ID: 15026078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new 2-carbamoyl pteridine that inhibits mycobacterial FtsZ.
    Reynolds RC; Srivastava S; Ross LJ; Suling WJ; White EL
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3161-4. PubMed ID: 15149666
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
    J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative structure-activity relationships of 2, 4-diamino-5-(2-X-benzyl)pyrimidines versus bacterial and avian dihydrofolate reductase.
    Selassie CD; Gan WX; Kallander LS; Klein TE
    J Med Chem; 1998 Oct; 41(22):4261-72. PubMed ID: 9784101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of ternary crystal complexes of F31 variants of human dihydrofolate reductase with NADPH and a classical antitumor furopyrimidine.
    Cody V; Galitsky N; Luft JR; Pangborn W; Blakley RL; Gangjee A
    Anticancer Drug Des; 1998 Jun; 13(4):307-15. PubMed ID: 9627670
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FlexE: efficient molecular docking considering protein structure variations.
    Claussen H; Buning C; Rarey M; Lengauer T
    J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selectively weakened binding of methotrexate by human dihydrofolate reductase allows rapid ex vivo selection of mammalian cells.
    Volpato JP; Mayotte N; Fossati E; Guerrero V; Sauvageau G; Pelletier JN
    J Mol Recognit; 2011; 24(2):188-98. PubMed ID: 21360609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
    Bastien D; Ebert MC; Forge D; Toulouse J; Kadnikova N; Perron F; Mayence A; Huang TL; Vanden Eynde JJ; Pelletier JN
    J Med Chem; 2012 Apr; 55(7):3182-92. PubMed ID: 22424148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system.
    Bowman AL; Lerner MG; Carlson HA
    J Am Chem Soc; 2007 Mar; 129(12):3634-40. PubMed ID: 17335207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Vasudevan A; Queener SF
    J Med Chem; 1997 Sep; 40(19):3032-9. PubMed ID: 9301665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stoichiometric selection of tight-binding inhibitors by wild-type and mutant forms of malarial (Plasmodium falciparum) dihydrofolate reductase.
    Kamchonwongpaisan S; Vanichtanankul J; Tarnchompoo B; Yuvaniyama J; Taweechai S; Yuthavong Y
    Anal Chem; 2005 Mar; 77(5):1222-7. PubMed ID: 15732900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
    Fogel GB; Cheung M; Pittman E; Hecht D
    J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.